ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GSK Gsk Plc

1,784.00
6.00 (0.34%)
Last Updated: 10:35:38
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Shares Traded Last Trade
  6.00 0.34% 1,784.00 692,561 10:35:38
Bid Price Offer Price High Price Low Price Open Price
1,783.50 1,784.50 1,785.00 1,766.50 1,780.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1428 15.59 76.84B
Last Trade Time Trade Type Trade Size Trade Price Currency
10:35:38 AT 198 1,784.00 GBX

Gsk (GSK) Latest News (15)

Gsk (GSK) Discussions and Chat

Gsk (GSK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
09:35:381,784.001983,532.32AT
09:35:381,784.0033588.72AT
09:35:381,783.503626,456.27AT
09:35:381,783.501502,675.25AT
09:35:381,783.501582,817.93AT

Gsk (GSK) Top Chat Posts

Top Posts
Posted at 24/5/2024 09:20 by Gsk Daily Update
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,778p.
Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £73,303,780,364.
Gsk has a price to earnings ratio (PE ratio) of 14.87.
This morning GSK shares opened at 1,780p
Posted at 24/5/2024 07:07 by panache1
Issued: 23 May 2024, London UK Statement: Zantac (ranitidine) litigation - Valadez and Williams cases · Jury in Valadez case in Illinois state court finds GSK not liable for plaintiff's colorectal cancer· Verdict is consistent with scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer· GSK will continue to vigorously defend itself against all other claims· Next Zantac trial (Williams) due to start in Illinois dismissed GSK plc (LSE/NYSE: GSK) welcomes today's jury verdict in the Valadez case in Illinois state court finding in GSK's favour in the first Zantac case to go to trial. This outcome is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer, supported by 16 epidemiological studies looking at human data regarding the use of ranitidine. GSK will continue to vigorously defend itself against all other claims. Prior to this verdict, the court rejected the Plaintiff's ability to request punitive damages. Separately, the company welcomed the recent court ruling dismissing the next Zantac trial (Williams) that was due to start on 23 May 2024. In the Williams case, the Illinois state court dismissed the case before trial on the basis that GSK was not the brand manufacturer of over-the-counter Zantac at the time the Plaintiff allegedly used it and should not be liable for any subsequent over-the-counter Zantac use. ?
Posted at 22/5/2024 16:06 by zho
GSK PLC (LSE:GSK, NYSE:GSK) may face a settlement of up to $2 billion to resolve thousands of lawsuits related to Zantac, a heartburn medication linked to cancer, according to an estimate from the investment banking arm of Barclays.

Zantac was pulled from the market in 2019 after the US Food and Drug Administration (FDA) found it contained N-nitrosodimethylamine (NDMA), a probable carcinogen. This discovery led to numerous lawsuits from patients who alleged that they developed cancer after using the drug.

The potential figure for GSK is informed by recent settlements by other pharmaceutical companies, notably Pfizer.

According to the Financial Times, Pfizer recently settled more than 10,000 US Zantac cases for up to $250 million, which sets a benchmark of approximately $25,000 per case. This figure has influenced Barclays' estimate of GSK's potential settlement costs.
Posted at 08/5/2024 11:17 by csalvage
Bernstein raises GSK price target to 2,560 (2,505) pence - 'outperform'
Posted at 02/5/2024 09:24 by geckotheglorious
II view

”GSK extends share price rally after very healthy results
The turnaround at this UK pharmaceutical giant continues following these well-received quarterly results. City writer Graeme Evans explains why investors keep chasing the shares higher.

Upgraded guidance and a bigger-than-expected quarterly dividend today moved GSK  shares closer to where they were prior to their summer 2022 Zantac-led crash.

The drugs giant plans to pay shareholders 15p a share on 11 July, which US bank Jefferies said compared with the City consensus of 14.7p and its own 14.5p estimate. Last year’s quarterly dividend was 14p.
The company continues to forecast a full-year payout of 60p a share, which is based on its policy of a 40-60% payout ratio through the investment cycle.

Shares rose 40p to 1,713p, taking gains for this year to 16%, after first-quarter revenues of £7.36 billion topped City hopes by 4% and led to a 16% beat on the earnings per share result of 43.1p.

The improvement was fuelled by strong sales of shingles vaccine Shingrix, which rose 18% to £945 million on the back of immunisation programmes in Australia and Europe, including the UK. It also benefited from earlier than anticipated supply to GSK’s partner in China.

Markets outside the US now represent more than 50% of global Shingrix sales, up from 40% the same quarter a year ago. The vaccine has been launched in 39 countries, the majority of which have average cumulative immunisation rates below 5%.

US sales decreased 7% against tougher comparatives, after the country’s immunisation rate at the end of 2023 reached 37% of the more than 120 million US adults currently recommended to receive Shingrix, up seven percentage points since the end of 2022.

Arexvy, a respiratory syncytial virus vaccine for older adults, recorded sales of £182 million following its launch in the US in the third quarter of last year. More than seven million of the country’s 83 million adults at risk have so far been protected by Arexvy.

In speciality medicines, strong performances in HIV, respiratory and immunology and oncology helped the division’s sales up by 17% to £2.5 billion. Total group sales rose 10% on a constant currency basis, with growth across the first half set to be stronger than the second due to tougher comparisons and the timing of Shingrix sales in China.

GSK’s forecasts for 2024 now point to turnover growth towards the upper part of the 5-7% range and core operating profit growth of 9% to 11% compared with 7-10% previously. Core earnings per share growth of 8% to 10% is up from 6-9% given at 2023 results.

The drugs pipeline now features 72 vaccines and specialty medicines, with 18 assets in the Phase III later stages of development.

Chief executive Emma Walmsley said: “We have made a strong start to 2024, with another quarter of excellent performance and continued pipeline progress, including positive data readouts for four phase III medicines.”

Taken together with other R&D achievements, she said GSK had strengthened its position in its key therapeutic areas of infectious diseases, HIV, respiratory/immunology and oncology.

She added: “We expect this strong momentum to continue, and look forward to delivering another year of meaningful growth in sales and earnings in 2024.”Shares are now within 100p of where they were two years ago prior to the disclosure of US litigation on heartburn drug Zantac. They were just 1,316p in July last year.
Jefferies is backing shares to reach 1,950p. It said today: “We are well above consensus 2026 estimates and believe long-acting HIV injectables, vaccines, and new pipeline launches mean profits likely face a blip not cliff on 2028 HIV patent expiries.

“We argue given this under-appreciated growth profile, the shares offer attractive risk-reward ahead of potential Zantac class action settlement.”

The Zantac issue has overshadowed the company’s attempts to convince the City of its standalone potential since splitting off consumer healthcare operation Haleon  in 2022.

It continues to defend itself against the claims but doing so has taken time, with cases scheduled in Illinois, Texas and Nevada between now and March 2025.

GSK reached a confidential settlement on a trial due to begin last month in California, a move it said reflected the company’s desire to avoid the distraction related to protracted litigation. It did not admit any liability in the settlement and said it would “continue to vigorously defend itself based on the facts and the science in all other Zantac cases”.
Posted at 03/4/2024 08:21 by geckotheglorious
GSK picking up momentum, says HL’s Clayton
GSK (GSK) is ‘fighting back into contention’ with a bumper crop of new product launches in the pipeline, says Hargreaves Lansdown manager Steve Clayton.

Clayton holds the Citywire Elite Companies AAA-rated pharmaceutical giant in his HL Select UK Income Shares fund, where it makes up 3% of the £138m portfolio.

The group has been focused on restructuring, with a spin out of its consumer division Haleon (HLN), and developing new medicines such as shingles vaccine Shingrix, which Clayton said is ‘already a multi-billion dollars a year product’.

The arrival of US activist investors Elliott Management a few years ago highlighted ‘the weak returns GSK had achieved, despite some real clinical strengths within the business’.

‘The company is now more optimistic about its research pipeline delivering more meaningful new drugs than for many years,’ Clayton said.

‘GSK’s business has more clarity about it these days and its current pipeline of 71 assets is predicted by GSK to contain at least 12 major new products to be launched from 2025 onwards.’

The shares dropped 2.5% to £16.65 on Tuesday, but have added almost 16% over the last 12 months.
Posted at 07/2/2024 21:09 by pj84
From yesterdays questor column

"GSK is performing well despite the legal clouds that hang over it
Questor share tip: more of its vaccines are proving their worth and the company’s valuation fails to reflect punchy growth forecasts

Russ Mould

6 February 2024 • 6:00am

Strong full-year numbers last week, a planned dividend rise in 2024 and upgraded medium-term growth and profit forecasts all support our confidence in GSK, where a blossoming drugs pipeline gives additional visibility and increases the chances of some reward for readers in the form of both capital appreciation and income.

A fourth dismissal or settlement of lawsuits relating to the heartburn treatment Zantac is also encouraging.

While the legal cloud regarding the drug and its allegedly carcinogenic side-effects is far from fully lifted, the market’s worst fears regarding possible liabilities are yet to be borne out and the shares still trade some 9pc below highs reached almost two years ago.

GSK still faces a lengthy list of cases, but the more that are settled, the greater the chance that investors can again focus on the day-to-day business, which is performing well.

The launch of the respiratory syncytial virus vaccine Arexvy is going well, judging by 2023’s sales tally of £1.2bn, which is already 4pc of the group total.

That nicely supplements the £3.4bn revenues from shingles vaccine Shingrix and helps the company to get over its embarrassing failure to match Pfizer, Moderna and AstraZeneca in the race to find a Covid vaccine.

GSK now has 71 vaccines and speciality medicines in its drug development pipeline, including 18 at the Phase III stage, and is hoping for a dozen to come to market from 2025 onwards in areas such as HIV, oncology and respiratory conditions.


This roadmap presumably underpins the upgrade to medium-term sales and profits growth targets offered by chief executive Dame Emma Walmsley alongside the full-year figures.

GSK now expects compound annual growth rates of 7pc in revenues and 11pc in earnings between 2021 and 2026. Such a rate of progress would suggest that a multiple of barely 12 times forecast earnings looks decent value, especially when it is supported by a yield of 3.6pc, based on management’s guidance for a 60p-a-share dividend in 2024.

GSK still looks like good value. Hold."
Posted at 11/1/2024 10:11 by anhar
MHRANGOON is correct that you have to adjust for the consolidation in order to compare current values with the pre-demerger value. You can't just look at the share prices alone to make a comparison with the pre-demerger value, you need to consider the number of shares involved.

The terms were that pre-demerger GSK holders received 1 HLN for every 1 GSK share held. Following that, GSK shares were consolidated at 4 for 5.

So assume for example you held 1,000 old GSK, then you would now have 1,000 HLN and 800 current GSK.

Using the above figures, the old GSK share price of 1,800p gives a value of £18,000 pre-dem.

With new GSK now at 1,570p the holding is worth £12,560 and HLN £3,370, a total of £15,930 which is a loss of £2,070 or 11.5% on the old GSK value. Clearly then, the combined holding would have to rise to £18,000 just to break even, which could be satisfied by GSK or HLN alone or some combination of the two.
Posted at 10/1/2024 18:17 by laurence llewelyn binliner
The pre split share price in summer 2022 was about 1800, and with the share price today at 1570, plus the HLN share price of 337 gives us c1900 total, so we are ahead again at last 18 months later..

GSK at 1800 stand alone would be great to see with HLN alongside adding value for those holders who kept them, as soon as they hit their debt to EBITDA ratio the dividend will pick up pace there too..
Posted at 15/11/2023 09:37 by abdullla
GSK share price going against the rise in the Ftse,getting ready for the double drop tomorrow due to X-div
Posted at 17/10/2023 14:40 by anhar
Correct TM. GSK is an outstanding example of all those styles:

Growth - after about a million years of holding, I'm up just 12.6% on original cost. This includes my HLN demerger shares. Not that I'm a growth player but that's the fact. Failed.

Income - This is my style. Divis were static for eight years at 80p for old GSK from 2014-2021 though admittedly there was a 20p special back in 2016. Following that payout paralysis, after the demerger the combined divis from new GSK and HLN were slashed. Failed.

Value - hard to see that GSK is underpriced with all that debt. Net debt at 30/6/23 was £18bn against net assets of £12bn and NAV is most certainly not above the share price. Failed.

So indeed GSK has something to offer these three approaches and it's ultra reliable. It fails all three.
Gsk share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock